I’m part of the Leerink Partners equity research team. Marty Huber, CEO, Mersana: It’s a Jonathan Chang, Equity Research, Leerink Partners: pleasure to host the management team of Mersana.

Operator: Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year End 2024 Conference Call. Currently all ...

KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, including ...

Not all rosy However, not everyone is convinced by the prospect of ADCs, including Roche’s current CEO, Severin Schwan ... last year shares in Mersana Therapeutics, a small biotech specialised ...

CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients with triple-negative breast cancer (TNBC) previously tr ...

Mersana's Q4 2024 EPS of -0.11 exceeded expectations, improving from the forecast of -0.15. Revenue for the quarter was $16.36 million, significantly above the forecast. The company ended 2024 ...

Mersana Therapeutics stock opened at $0.48 on Monday. The firm has a market cap of $59.30 million, a price-to-earnings ratio of -0.79 and a beta of 1.39. Mersana Therapeutics has a 1 year low of ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) – Wedbush decreased their Q1 2025 earnings estimates for Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush analyst D.